Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Martin S. Taylor(Massachusetts General Hospital), Connie Wu(Massachusetts General Hospital), Peter C. Fridy(Rockefeller University), Stephanie J. Zhang(Massachusetts General Hospital), Yasmeen Senussi(Massachusetts General Hospital), Justina C. Wolters(University Medical Center Groningen), Tatiana Cajuso(Dana-Farber Cancer Institute), Wen‐Chih Cheng(Dana-Farber Cancer Institute), John D. Heaps(Dana-Farber Cancer Institute), Bryant D. Miller(Dana-Farber Cancer Institute), Kei Mori(Massachusetts General Hospital), Limor Cohen(Harvard University Press), Hua Jiang(Rockefeller University), Kelly R. Molloy(Rockefeller University), Brian T. Chait(Rockefeller University), Michael Goggins(Johns Hopkins University), Irun Bhan(Massachusetts General Hospital), Joseph W. Franses(Massachusetts General Hospital), Xiaoyu Yang(Dana-Farber Cancer Institute), Mary‐Ellen Taplin(Dana-Farber Cancer Institute), Xinan Wang(Harvard University), David C. Christiani(Harvard University), Bruce E. Johnson(Dana-Farber Cancer Institute), Matthew Meyerson(Dana-Farber Cancer Institute), Ravindra Uppaluri(Brigham and Women's Hospital), Ann Marie Egloff(Brigham and Women's Hospital), Elyssa N. Denault(Massachusetts General Hospital), Laura M. Spring(Massachusetts General Hospital), Tian‐Li Wang(Johns Hopkins University), Ie‐Ming Shih(Johns Hopkins University), Jennifer E. Fairman(Johns Hopkins University), Euihye Jung(University of Pennsylvania), Kshitij S. Arora(Louisiana State University in Shreveport), Osman H. Yilmaz(Beth Israel Deaconess Medical Center), Sonia Cohen(Massachusetts General Hospital), Tatyana Sharova(Massachusetts General Hospital), Gary Chi(Massachusetts General Hospital), Bryanna L. Norden(Massachusetts General Hospital), Yuhui Song(Massachusetts General Hospital), Linda T. Nieman(Massachusetts General Hospital), Leontios Pappas(Massachusetts General Hospital), Aparna R. Parikh(Massachusetts General Hospital), Matthew R. Strickland(Massachusetts General Hospital), Ryan B. Corcoran(Massachusetts General Hospital), Tomas Mustelin(University of Washington), George Eng(Massachusetts General Hospital), Ömer H. Yilmaz(Beth Israel Deaconess Medical Center), Ursula A. Matulonis(Dana-Farber Cancer Institute), Andrew T. Chan(Harvard University), Steven J. Skates(Massachusetts General Hospital), Bo R. Rueda(Massachusetts General Hospital), Ronny Drapkin(University of Pennsylvania), Samuel J. Klempner(Massachusetts General Hospital), Vikram Deshpande(Massachusetts General Hospital), David T. Ting(Massachusetts General Hospital), Michael P. Rout(Rockefeller University), John LaCava(University Medical Center Groningen), David R. Walt(Massachusetts General Hospital), Kathleen H. Burns(Massachusetts General Hospital)
Cancer Discovery
September 12, 2023
Cited by 82Open Access
Full Text

Abstract

Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10-17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring. SIGNIFICANCE: The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring. See related commentary by Doucet and Cristofari, p. 2502. This article is featured in Selected Articles from This Issue, p. 2489.


Related Papers

No related papers found

Powered by citation graph analysis